866-997-4948(US-Canada Toll Free)

Women's Health Therapeutics Market to 2017 - High Unmet Need will Drive Uptake of Novel Drugs Such as Prolia and Odanocantib in the Menopause and Osteoporosis Market

Published By :

GBI Research

Published Date : Jan 2012

Category :

Therapeutic Area

No. of Pages : 114 Pages

 

GBI Research, a leading business intelligence provider, has released its latest research “Women’s Health Therapeutics Market to 2017 - High Unmet Need will Drive Uptake of Novel Drugs Such as Prolia and Odanocantib in the Menopause and Osteoporosis Market”. The report provides in-depth analysis of the drivers and barriers that affect the global Women’s Health market and analyzes the markets for women’s health disorders in the US, the top five markets in Europe (the UK, Germany, France, Italy and Spain) and Japan. 

 

Treatment usage patterns, revenues and annual cost of therapy are forecast until 2017 for the key geographies, as well as for the leading therapeutic segments. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that have shaped the global market.

 

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

 

GBI Research finds that the women’s health therapeutics market will grow rapidly, largely due to the introduction of new therapies and the increased awareness among patients and physicians in two of the largest segments within WH disorders, the menopause and osteoporosis. Novel non-hormonal therapeutics will become more popular during the forecast period. Though many of the major selling drugs in the osteoporosis market are set to lose patent protection in 2012, the launch of effective therapies such as Prolia (recently launched in 2010) will drive the market revenues. 

 

The overall women’s health therapeutics market is driven by postmenopausal osteoporosis and menopause. The endometriosis market is heavily genericized and lacks an effective and safe option for the treatment of endometriosis. In 2010, the women’s health therapeutics market was estimated to be worth $14,530m. GBI Research forecasts the market to grow at a Compound Annual Growth Rate (CAGR) of 7.9% between 2010 and 2017 to record a sales value of $24,671m in 2017. 

 

The market has considerable unmet need, as the majority of the diseases in the market are served by hormonal therapeutics. Hormones have been shown to be associated with significant safety issues such as risks of breast cancer and cardiovascular disease. Hence, the use of hormones has declined and women are worried about resuming hormonal therapy for the treatment of the menopause/osteoporosis. There is an opportunity for pharmaceutical companies to develop drugs with greater safety profiles and more competitive prices. 

 

The women’s health therapeutics market R&D pipeline is moderately strong, with the majority of first-in-class drugs in late stages of development. These drugs are expected to drive market revenues and it is expected that, if they are approved and are shown to have better safety profiles, patients will comply with novel therapies. In particular, non-hormones are set to take over the conventional hormone therapeutics market.

 

Scope

 

  • Annualized market data for the women’s health disorders market from 2002 to 2010, forecast to 2017.
  • Analysis of the leading therapeutic segments, including endometriosis, postmenopausal osteoporosis, menopause and urinary incontinence 
  • Analysis of the women’s health therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan 
  • Market characterization of the women’s health therapeutics market, including market size, annual cost of therapy and treatment usage patterns 
  • Key drivers and barriers that have a significant impact on the market 
  • Coverage of pipeline molecules in various phases of drug development 
  • Competitive benchmarking of leading companies. The key companies studied in this report are Pfizer, Inc., Eli Lilly and Company, F. Hoffman-La Roche Ltd., Merck and Warner Chilcott Plc.
  • Key M&A activities and licensing agreements that took place in 2010 in the women’s health therapeutics market

 

Reasons to buy

 

  • Align your product portfolio to the markets with high growth potential.
  • Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
  • Develop key strategic initiatives by understanding the key focus areas of leading companies. 
  • Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

Table of Contents

 

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

 

2 Women\'s Health Therapeutics Market to 2017 - Introduction

2.1 GBI Research Report Guidance

 

3 Women\'s Health Therapeutics Market to 2017 - Market Overview

3.1 Introduction

3.2 Revenue Forecasts for Women\'s Health Therapeutics Market

3.2.1 Revenues

3.2.2 Annual Cost of Therapy

3.2.3 Generic Share

3.3 Treatment Usage Patterns

3.4 Drivers and Barriers for Women\'s Health Therapeutics Market

3.4.1 Drivers for Women\'s Health Therapeutics Market

3.4.2 Barriers for Women\'s Health Therapeutics Market

 

4 Women\'s Health Therapeutics Market to 2017 - Geographical Landscape

4.1 The US

4.1.1 Revenue

4.1.2 Annual Cost of Therapy

4.1.3 Treatment Usage Pattern

4.2 Top Five Countries of Europe

4.2.1 Revenue

4.2.2 Annual Cost of Therapy

4.2.3 Treatment Usage Pattern

4.3 Japan

4.3.1 Revenue

4.3.2 Annual Cost of Therapy

4.3.3 Treatment Usage Pattern

 

5 Women\'s Health Therapeutics Market to 2017 - Therapeutic Landscape

5.1 Menopause

5.1.1 Introduction

5.1.2 Revenues

5.1.3 Generic Share

5.1.4 Annual Cost of Therapy

5.1.5 Treatment Usage Patterns

5.1.6 Drivers and Barriers for Menopause

5.2 Post Menopausal Osteoporosis

5.2.1 Introduction

5.2.2 Revenues

5.2.3 Generic Share

5.2.4 Annual Cost of Therapy

5.2.5 Treatment Usage Patterns

5.2.6 Treatment Flow Algorithm

5.2.7 Drivers and Barriers for Post Menopausal Osteoporosis

5.3 Endometriosis

5.3.1 Introduction

5.3.2 Revenues

5.3.3 Generic Share

5.3.4 Annual Cost of Therapy

5.3.5 Treatment Usage Patterns

5.3.6 Treatment Flow Algorithm

5.3.7 Drivers and Barriers for Endometriosis

5.4 Urinary Incontinence

5.4.1 Introduction

5.4.2 Revenues

5.4.3 Generic Share

5.4.4 Annual Cost of Therapy

5.4.5 Treatment Usage Patterns

5.4.6 Treatment Flow Algorithm

5.4.7 Drivers and Barriers for Urinary Incontinence

 

6 Women\'s Health Therapeutics Market to 2017 - Pipeline Analysis

6.1 Introduction

6.1.1 Research and Development Pipeline - Menopause

6.1.2 Research and Development Pipeline - Postmenopausal Osteoporosis

6.1.3 Research and Development Pipeline - Endometriosis

6.1.4 Research and Development Pipeline - Urinary Incontinence

6.2 Profiles of Promising Drugs in the Women\'s Health Therapeutics Market

6.2.1 Aprela (Bazedoxifene/Conjugated Estrogen)

6.2.2 Pristiq (Desvenlaxafine, DVS-233)

6.2.3 Visanne

6.2.4 Elagolix (NBI-56418)

6.2.5 Odanacatib (MK-0822)

6.2.6 Viviant (Bazedoxifene)

6.2.7 YM178

6.2.8 GRC 6211

 

7 Women\'s Health Therapeutics Market to 2017- Competitive Landscape

7.1 Market Share Analysis - Women\'s Health Therapeutics Market

7.2 Major Marketed Products: Women\'s Health Therapeutics Market

7.2.1 Detrol (tolterodine tartrate)

7.2.2 Premarin

7.2.3 Evista (raloxifene hydrochloride)

7.2.4 Actonel (Risedronate sodium)

7.3 Competitive Profiling

7.3.1 Pfizer

7.3.2 Eli-Lilly

7.3.3 Merck

7.3.4 Roche

7.3.5 Warner Chilcott

 

8 Women\'s Health Therapeutics Market to 2017 - M&A Landscape

8.1 M&A Landscape

8.1.1 M&A Deals by Year

8.1.2 M&A Deals by Deal Type

8.1.3 M&A Deals by Geography

8.1.4 M&A Deals by Value

8.1.5 Top Five M&A Deals by Value

8.2 R&D Licensing Agreements

8.2.1 Deals by Year

8.2.2 Deals by Geography

8.2.3 Deals by Value ($)

8.3 Co-Development Agreements

8.3.1 Co-Development Agreements by Year

8.3.2 Co-Development Agreements by Geography

8.3.3 Co-Development Agreements by Value

 

9 Women\'s Health Therapeutics Market to 2017 - Appendix

9.1 Market Definitions

9.2 Abbreviations

9.3 Research Methodology

9.3.1 Coverage

9.3.2 Secondary Research

9.3.3 Primary Research

9.3.4 Section Wise Methodology

9.3.5 Expert Panel Validation

9.4 Contact Us

9.5 Disclaimer

9.6 Sources

List of Table

Table 1: Women\'s Health Therapeutics Market, Global, Revenue, ($m), 2002 - 2010

Table 2: Women\'s Health Therapeutics Market, Global, Revenue Forecasts, ($m), 2010 - 2017

Table 3: Women\'s Health Therapeutics Market, Global, Revenue by Geography, ($m), 2002 - 2010

Table 4: Women\'s Health Therapeutics Market, Global, Revenue by Geography, ($m), 2010 - 2017

Table 5: Women\'s Health Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002 - 2010

Table 6: Women\'s Health Therapeutics Market, Global, Annual Cost of Therapy, ($), 2010 - 2017

Table 7: Women\'s Health Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002 - 2010

Table 8: Women\'s Health Therapeutics Market, Global, Treatment Usage Patterns, (million), 2010 - 2017

Table 9: Women\'s Health Therapeutics Market, The US, Revenue, ($m), 2002 - 2010

Table 10: Women\'s Health Therapeutics Market, The US, Revenue Forecasts, ($m), 2010 - 2017

Table 11: Women\'s Health Therapeutics Market, The US, Annual Cost of Therapy ($), 2002 - 2010

Table 12: Women\'s Health Therapeutics Market, The US, Annual Cost of Therapy ($), 2010 - 2017

Table 13: Women\'s Health Therapeutics Market, The US, Treatment Usage Patterns, (million), 2002 - 2010

Table 14: Women\'s Health Therapeutics Market, The US, Treatment Usage Patterns, (million), 2010 - 2017

Table 15: Women\'s Health Therapeutics Market, Top Five Countries of Europe, Revenue, ($m), 2002 - 2010

Table 16: Women\'s Health Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts, ($m), 2010 - 2017

Table 17: Women\'s Health Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy, ($), 2002-2010

Table 18: Women\'s Health Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy, ($), 2010 - 2017

Table 19: Women\'s Health Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns, (million), 2002 - 2010

Table 20: Women\'s Health Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns, (million), 2010 - 2017

Table 21: Women\'s Health Therapeutics Market, Japan, Revenue, ($m), 2002 - 2010

Table 22: Women\'s Health Therapeutics Market, Japan, Revenue Forecasts, ($m), 2010 - 2017

Table 23: Women\'s Health Therapeutics Market, Japan, Annual Cost of Therapy, ($), 2002 - 2010

Table 24: Women\'s Health Therapeutics Market, Japan, Annual Cost of Therapy, ($), 2010- 2017

Table 25: Women\'s Health Therapeutics Market, Japan, Treatment Usage Patterns, (million), 2002 - 2010

Table 26: Women\'s Health Therapeutics Market, Japan, Treatment Usage Patterns, (million), 2010 - 2017

Table 27: Menopause Therapeutics Market, Global, Revenue, ($m), 2002 - 2010

Table 28: Menopause Therapeutics Market, Global, Revenue Forecasts, ($m), 2010 - 2017

Table 29: Menopause Therapeutics Market, Global, Revenue by Geography, ($m), 2002 - 2010

Table 30: Menopause Therapeutics Market, Global, Revenue by Geography, ($m), 2010 -2017

Table 31: Menopause Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002 - 2010

Table 32: Menopause Therapeutics Market, Global, Annual Cost of Therapy, ($), 2010 - 2017

Table 33: Menopause Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002 - 2010

Table 34: Menopause Therapeutics Market, Global, Treatment Usage Patterns, (million), 2010 - 2017

Table 35: Post Menopausal Osteoporosis Therapeutics Market, Global, Revenue, ($m), 2002 - 2010

Table 36: Post Menopausal Osteoporosis Therapeutics Market, Global, Revenue Forecasts, ($m), 2010 - 2017

Table 37: Post Menopausal Osteoporosis Therapeutics Market, Global, Revenue by Geography, ($m), 2002 - 2010

Table 38: Post Menopausal Osteoporosis Therapeutics Market, Global, Revenue by Geography, ($m), 2010 - 2017

Table 39: Post Menopausal Osteoporosis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002 - 2010

Table 40: Post Menopausal Osteoporosis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2010 - 2017

Table 41: Post Menopausal Osteoporosis Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002 - 2010

Table 42: Post Menopausal Osteoporosis Therapeutics Market, Global, Treatment Usage Patterns, (million), 2010 - 2017

Table 43: Endometriosis Therapeutics Market, Global, Revenue, ($m), 2002 - 2010

Table 44: Endometriosis Therapeutics Market, Global, Revenue Forecasts, ($m), 2010 - 2017

Table 45: Endometriosis Therapeutics Market, Global, Revenue by Geography, ($m), 2002 - 2010

Table 46: Endometriosis Therapeutics Market, Global, Revenue by Geography, ($m), 2010 - 2017

Table 47: Endometriosis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2010

Table 48: Endometriosis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2010-2017

Table 49: Endometriosis Therapeutics Market, Global, Treatment Usage Patterns, (\'000), 2002 - 2010

Table 50: Endometriosis Therapeutics Market, Global, Treatment Usage Patterns, (\'000), 2010 - 2017

Table 51: Urinary Incontinence Therapeutics Market, Global, Revenue, ($m), 2002 - 2010

Table 52: Urinary Incontinence Therapeutics Market, Global, Revenue Forecasts, ($m), 2010 - 2017

Table 53: Urinary Incontinence Therapeutics Market, Global, Revenue by Geography, ($m), 2002 - 2010

Table 54: Urinary Incontinence Therapeutics Market, Global, Revenue by Geography, ($m), 2010 - 2017

Table 55: Urinary Incontinence Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002 - 2010

Table 56: Urinary Incontinence Therapeutics Market, Global, Annual Cost of Therapy, ($), 2010 - 2017

Table 57: Urinary Incontinence Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002 - 2010

Table 58: Urinary Incontinence Therapeutics Market, Global, Treatment Usage Patterns, (million), 2010 - 2017

Table 59: Women\'s Health Therapeutics Market, Global, Pipeline by Phase, 2011

Table 60: Women\'s Health Therapeutics Market, Global, Pipeline by Indication, 2011

Table 61: Menopause Therapeutics Market, Global, Pipeline, Pre-Clinical Stage Molecules, 2011

Table 62: Menopause Therapeutics Market, Global, Pipeline, IND Filed Stage Molecules, 2011

Table 63: Menopause Therapeutics Market, Global, Pipeline, Phase II Stage Molecules, 2011

Table 64: Menopause Therapeutics Market, Global, Pipeline, Phase III Stage Molecules, 2011

Table 65: Menopause Therapeutics Market, Global, Pipeline, NDA Filed Molecules, 2011

Table 66: Postmenopausal Osteoporosis Therapeutics Market, Global, Pipeline, Phase I Stage Molecules, 2011

Table 67: Postmenopausal Osteoporosis Therapeutics Market, Global, Pipeline, Phase II Stage Molecules, 2011

Table 68: Postmenopausal Osteoporosis Therapeutics Market, Global, Pipeline, Phase III Stage Molecules, 2011

Table 69: Postmenopausal Osteoporosis Therapeutics Market, Global, Pipeline, NDA Filed Molecules, 2011

Table 70: Endometriosis Therapeutics Market, Pipeline, Global, Pre-Clinical Stage Molecules, 2011

Table 71: Endometriosis Therapeutics Market, Global, Pipeline, Phase I Stage Molecules, 2011

Table 72: Endometriosis Therapeutics Market, Global, Pipeline, Phase II Stage Molecules, 2011

Table 73: Endometriosis Therapeutics Market, Global, Pipeline, Phase III Stage Molecules, 2011

Table 74: Urinary Incontinence Therapeutics Market, Global, Pipeline, Pre-Clinical Stage Molecules, 2011

Table 75: Urinary Incontinence Therapeutics Market, Global, Pipeline, Phase I Stage Molecules, 2011

Table 76: Urinary Incontinence Therapeutics Market, Global, Pipeline, Phase II Stage Molecules, 2011

Table 77: Urinary Incontinence Therapeutics Market, Global, Pipeline, Phase III Stage Molecules, 2011

Table 78: Urinary Incontinence Therapeutics Market, Global, Pipeline, NDA Filed Molecules, 2011

Table 79: Women\'s Health Therapeutics Market, Marketed Drug Revenues, 2010

Table 80: Women\'s Health Therapeutics Market, Global, M&A Deals by Type, 2004-2011

Table 81: Women\'s Health Therapeutics Market, Global, M&A Deals by Geography, 2004-2011

Table 82: Women\'s Health Therapeutics Market, Global, M&A Deals by Value, 2004-2011

Table 83: Women\'s Health Therapeutics Market, Global, Top Five M&A Deals by Value, ($m), 2005-2010

Table 84: Women\'s Health Therapeutics Market, Global, Licensing Agreements by Geography, 2004-2011

Table 85: Women\'s Health Therapeutics Market, Global, Licensing Agreements by Value, ($m), 2004-2011

Table 86: Women\'s Health Therapeutics Market, Global, Co-Development Agreements by Geography, 2004-2011

Table 87: Women\'s Health Therapeutics Market, Global, Co-Development Agreements by Value, ($m), 2004-2011

List of Chart

 

Figure 1: Women\'s Health Therapeutics Market, Global, Revenue Forecasts, ($m), 2002 - 2017

Figure 2: Women\'s Health Therapeutics Market, Global, Revenue by Geography, ($m), 2002 - 2017

Figure 3: Women\'s Health Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002 - 2017

Figure 4: Women\'s Health Therapeutics Market, Global, Branded and Generic Share, (%), 2010 and 2017

Figure 5: Women\'s Health Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002 - 2017

Figure 6: Women\'s Health Therapeutics Market, Global, Drivers and Barriers, 2010

Figure 7: Women\'s Health Therapeutics Market, The US, Revenue Forecasts, ($m), 2002 - 2017

Figure 8: Women\'s Health Therapeutics Market, The US, Annual Cost of Therapy ($), 2002 - 2017

Figure 9: Women\'s Health Therapeutics Market, The US, Treatment Usage Patterns, (million), 2002 - 2017

Figure 10: Women\'s Health Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts, ($m), 2002 - 2017

Figure 11: Women\'s Health Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy, ($), 2002 - 2017

Figure 12: Women\'s Health Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns, (million), 2002 - 2017

Figure 13: Women\'s Health Therapeutics Market, Japan, Revenue Forecasts, ($m), 2002 - 2017

Figure 14: Women\'s Health Therapeutics Market, Japan, Annual Cost of Therapy, ($), 2002 - 2017

Figure 15: Women\'s Health Therapeutics Market, Japan, Treatment Usage Patterns, (million), 2002 - 2017

Figure 16: Menopause Therapeutics Market, Global, Revenue Forecasts, ($m), 2002 - 2017

Figure 17: Menopause Therapeutics Market, Global, Revenue by Geography, ($m), 2002 - 2017

Figure 18: Menopause Therapeutics Market, Global, Branded and Generic Share, (%), 2010 and 2017

Figure 19: Menopause Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002 - 2017

Figure 20: Menopause Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002 - 2017

Figure 21: Menopause Therapeutics Market, Global, Drivers and Barriers, 2010

Figure 22: Post Menopausal Osteoporosis Therapeutics Market, Global, Revenue Forecasts, ($m), 2002 - 2017

Figure 23: Post Menopausal Osteoporosis Therapeutics Market, Global, Revenue by Geography, ($m), 2002 - 2017

Figure 24: Post Menopausal Osteoporosis Therapeutics Market, Global, Branded and Generic Share, (%), 2010 and 2017

Figure 25: Post Menopausal Osteoporosis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002 - 2017

Figure 26: Post Menopausal Osteoporosis Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002 - 2017

Figure 27: Post Menopausal Osteoporosis Therapeutics Market, Treatment Flow Algorithm, 2010

Figure 28: Post Menopausal Osteoporosis Therapeutics Market, Global, Drivers and Barriers, 2010

Figure 29: Endometriosis Therapeutics Market, Global, Revenue Forecasts, ($m), 2002 - 2017

Figure 30: Endometriosis Therapeutics Market, Global, Revenue by Geography, ($m), 2002 - 2017

Figure 31: Endometriosis Therapeutics Market, Global, Branded and Generic Share, (%), 2010 and 2017

Figure 32: Endometriosis Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002-2017

Figure 33: Endometriosis Therapeutics Market, Global, Treatment Usage Patterns, (\'000), 2002 - 2017

Figure 34: Endometriosis Therapeutics Market, Treatment Flow Algorithm, 2010

Figure 35: Endometriosis Therapeutics Market, Global, Drivers and Barriers, 2010

Figure 36: Urinary Incontinence Therapeutics Market, Global, Revenue Forecasts, ($m), 2002 - 2017

Figure 37: Urinary Incontinence Therapeutics Market, Global, Revenue by Geography, ($m), 2002 - 2017

Figure 38: Urinary Incontinence Therapeutics Market, Global, Branded and Generic Share, (%), 2010 and 2017

Figure 39: Urinary Incontinence Therapeutics Market, Global, Annual Cost of Therapy, ($), 2002 - 2017

Figure 40: Urinary Incontinence Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002 - 2017

Figure 41: Women\'s health Therapeutics to 2017, UI Treatment Algorithm Part-1

Figure 42: Women\'s Health Therapeutics to 2017, UI Treatment Algorithm, Part-2

Figure 43: Urinary Incontinence Therapeutics Market, Global, Drivers and Barriers, 2010

Figure 44: Women\'s Health Therapeutics Market, Global, Pipeline by Phase, (%), 2011

Figure 45: Women\'s Health Therapeutics Market, Global, Pipeline by Indication (%), 2011

Figure 46: Women\'s Health Therapeutics Market, Market Share Analysis, (%), 2010

Figure 47: Women\'s Health Therapeutics Market, Pfizer SWOT Analysis, 2011

Figure 48: Women\'s Health Therapeutics Market, Eli-Lilly SWOT Analysis, 2011

Figure 49: Women\'s Health Therapeutics Market, Merck SWOT Analysis, 2011

Figure 50: Women\'s Health Therapeutics Market, Roche SWOT Analysis, 2011

Figure 51: Women\'s Health Therapeutics Market, Warner Chilcott SWOT Analysis, 2011

Figure 52: Women\'s Health Therapeutics Market, Global, M&A Deals by Year, 2004-2011

Figure 53: Women\'s Health Therapeutics Market, Global, M&A Deals by Type, (%), 2004-2011

Figure 54: Women\'s Health Therapeutics Market, Global, M&A Deals by Geography, (%), 2004-2011

Figure 55: Women\'s Health Therapeutics Market, Global, M&A Deals by Value, (%), 2004-2011

Figure 56: Women\'s Health Therapeutics Market, Global, Licensing Agreements by Year, 2004-2011

Figure 57: Women\'s Health Therapeutics Market, Global, Licensing Agreements by Geography, (%), 2004-2011

Figure 58: Women\'s Health Therapeutics Market, Global, Licensing Agreements by Value, (%), 2004-2011

Figure 59: Women\'s Health Therapeutics Market, Global, Co-Development Agreements by Year, 2004-2011

Figure 60: Women\'s Health Therapeutics Market, Global, Co-Development Agreements by Geography, (%), 2004-2011

Figure 61: Women\'s Health Therapeutics Market, Global, Co-Development Agreements by Value, (%), 2004-2011

Figure 62: GBI Research Market Forecasting Model

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *